Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer
Part of paid clinical trials in Tempe, Arizona.
- Sponsor
- Eli Lilly and Company
- Study ID
- NCT03382912
- Phase
- PHASE2
- Status
- Terminated
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Pegilodecakin — BIOLOGICALPegilodecakin plus Nivolumab
- Nivolumab — DRUGNivolumab Alone
Study Details
To compare the efficacy of pegilodecakin in combination with nivolumab versus nivolumab alone in participants with metastatic non-small cell lung cancer as measured by objective response rate.
Key Dates
- Start date
- Mar 22, 2018
- Status verified
- Jun 2020
- Primary completion
- Aug 28, 2019
- Completion
- Mar 3, 2020
Study Design
- Enrollment
- 52 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Pegilodecakin+NivolumabParticipants received Pegilodecakin subcutaneously at 0.8 milligrams (mg) (≤80 kilograms (kg) body weight) or 1.6 mg (\>80 kg body weight) once daily (QD) in the abdomen, thigh or back of upper arm. Nivolumab administered on day 1 of each 14 or 28 day cycle over approximately 30 minutes intravenous (IV) infusion at 240 mg every 2 weeks (Q2W), or 480 mg every 4 weeks (Q4W).
- Active Comparator: NivolumabParticipants received Nivolumab on day 1 of each 14- or 28- day cycle over approximately 30 minutes intravenous (IV) infusion at 240 mg every two weeks (Q2W), or 480 mg every 4 weeks (Q4W).
Primary Outcome Measure
Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)] [ Time Frame: From Date of Randomization to Progressive Disease, Death from Any cause (Up to 6 months after the last participant randomized) ]
Locations (35)
Find similar trials in Tempe, AZ
By condition
By specialty
By research site
Related Studies
- The Effect of Beta-glucan in Non-Small Cell Lung CancerRecruiting · University of Louisville · Louisville, Kentucky
- Dabrafenib and/or Trametinib Rollover StudyPHASE4 · Recruiting · Novartis Pharmaceuticals · Scottsdale, Arizona
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Study of NEO-201 in Solid Tumors Expansion CohortsPHASE1/PHASE2 · Recruiting · Precision Biologics, Inc · Bethesda, Maryland